Is Lurbinectedin FDA-Approved for Ovarian Cancer?
No, lurbinectedin (brand name Zepzelca) is not FDA-approved for ovarian cancer. The FDA granted accelerated approval in June 2020 solely for adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.[1]
What Is Lurbinectedin Used For?
Lurbinectedin targets the transcription process in cancer cells, leading to tumor cell death. Its only FDA-approved indication remains SCLC. It's administered intravenously every 21 days, often with supportive medications to manage side effects like neutropenia and fatigue.[1][2]
Is It Used Off-Label for Ovarian Cancer?
Some clinical studies have explored lurbinectedin in platinum-resistant ovarian cancer, often combined with other agents like doxorubicin or pembrolizumab. For example, phase II trials showed partial responses in about 25-30% of patients, but these results did not lead to FDA approval.[3] Off-label use occurs in practice based on physician discretion, but lacks regulatory backing and may not be covered by insurance.
What Ovarian Cancer Treatments Are FDA-Approved?
Standard options for advanced or recurrent ovarian cancer include:
- PARP inhibitors like olaparib (Lynparza) for BRCA-mutated cases.
- Bevacizumab (Avastin) combined with chemotherapy.
- Antibody-drug conjugates like mirvetuximab soravtansine (Elahere) for FRα-positive platinum-resistant disease.
Lurbinectedin is not among them.[1][4]
Ongoing Trials or Future Approval Chances?
Active trials (e.g., NCT04722647) test lurbinectedin in ovarian cancer combinations, but no phase III data supports pending approval. Patent exclusivity for Zepzelca runs through at least 2031, with no ovarian-specific extensions listed.[5] Check ClinicalTrials.gov for updates.
Sources
[1]: FDA Approval Summary for Zepzelca
[2]: Zepzelca Prescribing Information
[3]: PubMed: Lurbinectedin in Ovarian Cancer Trials
[4]: FDA Ovarian Cancer Approvals
[5]: DrugPatentWatch: Zepzelca Patents